|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US20140200261A1
(en)
|
2013-01-17 |
2014-07-17 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
DE202015010000U1
(de)
|
2014-12-12 |
2023-07-03 |
CureVac SE |
Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
|
|
EP3233132A4
(en)
*
|
2014-12-19 |
2018-06-27 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
CA3002912A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
|
JP7091255B2
(ja)
|
2016-05-06 |
2022-06-27 |
アイオニス・ファーマシューティカルズ・インコーポレイテッド |
Ｇｌｐ－１受容体リガンド部分コンジュゲート化オリゴヌクレオチドおよびその使用
|
|
MA45052A
(fr)
*
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
WO2017201347A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
BR112019000195A2
(pt)
|
2016-07-07 |
2019-04-24 |
Rubius Therapeutics, Inc. |
composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
CN110121558B
(zh)
*
|
2016-11-28 |
2023-06-13 |
日商那帕洁制药股份有限公司 |
化学修饰siRNA
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
WO2018186704A1
(ko)
*
|
2017-04-06 |
2018-10-11 |
포항공과대학교 산학협력단 |
무항생제 플라스미드 유지 시스템에서 플라스미드 카피 수의 정량적 조절 방법
|
|
US11390854B2
(en)
|
2017-05-09 |
2022-07-19 |
Fundacion Para La Investigacion Medica Aplicada |
Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
ES2983060T3
(es)
|
2017-08-18 |
2024-10-21 |
Modernatx Inc |
Variantes de ARN polimerasa
|
|
WO2019036683A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
ANALYTICAL METHODS BY HPLC
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
JP2021514190A
(ja)
*
|
2018-02-19 |
2021-06-10 |
コンバインド セラピューティクス インコーポレイテッドＣｏｍｂｉｎｅｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
コード化リボ核酸の器官保護発現および調節のための組成物および方法
|
|
GB201714430D0
(en)
*
|
2017-09-07 |
2017-10-25 |
Micol Romain |
Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
US20200268898A1
(en)
*
|
2017-11-08 |
2020-08-27 |
Astrazeneca Ab |
Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
|
|
CN111712468A
(zh)
|
2017-12-22 |
2020-09-25 |
北卡罗莱纳州立大学 |
聚合物荧光团、包含其的组合物及制备和使用其的方法
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
CN113271926A
(zh)
|
2018-09-20 |
2021-08-17 |
摩登纳特斯有限公司 |
脂质纳米颗粒的制备及其施用方法
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
CN113795579A
(zh)
|
2019-02-20 |
2021-12-14 |
摩登纳特斯有限公司 |
用于共转录加帽的rna聚合酶变体
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
CA3132975A1
(en)
|
2019-03-11 |
2020-09-17 |
Modernatx, Inc. |
Fed-batch in vitro transcription process
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
WO2020204130A1
(ja)
*
|
2019-04-05 |
2020-10-08 |
国立大学法人京都大学 |
Ｒｎａのキャッピング方法、修飾ｒｎａの製造方法、及び修飾ｒｎａ
|
|
CN114222818B
(zh)
|
2019-07-02 |
2025-07-08 |
基础应用医学研究基金会 |
cPLA2e诱导剂及其用途
|
|
EP3901261A1
(en)
|
2020-04-22 |
2021-10-27 |
BioNTech RNA Pharmaceuticals GmbH |
Coronavirus vaccine
|
|
IL300247A
(en)
|
2020-07-31 |
2023-03-01 |
Combined Therapeutics Inc |
Compositions and methods for improving vaccination
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3193508A1
(en)
*
|
2020-09-23 |
2022-03-31 |
Myeloid Therapeutics, Inc. |
Improved methods and compositions for expression of nucleic acids in cells
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
MX2023015487A
(es)
*
|
2021-06-24 |
2024-04-10 |
Hanmi Pharmaceutical Co Ltd |
Región 5' no traducida no natural y región 3' no traducida y uso de estas.
|
|
WO2023277168A1
(ja)
|
2021-06-30 |
2023-01-05 |
協和キリン株式会社 |
ポリヌクレオチド及び医薬組成物
|
|
KR20230017730A
(ko)
*
|
2021-07-27 |
2023-02-06 |
에스케이바이오사이언스(주) |
단백질 발현을 위한 mRNA와 이를 위한 주형
|
|
KR20240090727A
(ko)
|
2021-10-22 |
2024-06-21 |
세일 바이오메디슨스, 인크. |
Mrna 백신 조성물
|
|
CN118488834A
(zh)
|
2021-11-23 |
2024-08-13 |
赛欧生物医药股份有限公司 |
细菌源性脂质组合物和其用途
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
US12529047B1
(en)
|
2021-12-21 |
2026-01-20 |
Modernatx, Inc. |
mRNA quantification methods
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
US20250320254A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Circulating Factors
|
|
US20250319115A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Cytokines
|
|
JP2025517969A
(ja)
|
2022-05-25 |
2025-06-12 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
腫瘍抑制因子及び癌遺伝子の調節のための組成物及び方法
|
|
EP4641202A3
(en)
|
2022-05-25 |
2026-01-21 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulation of immune responses
|
|
CA3253328A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Modulation Methods of Genetic Drivers
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2024035733A1
(en)
*
|
2022-08-08 |
2024-02-15 |
The Curators Of The University Of Missouri |
Fasl-modified plg scaffolds enhances differentiation of stem cell derived beta cells
|
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
CN121057577A
(zh)
|
2023-01-27 |
2025-12-02 |
赛欧生物医药股份有限公司 |
经修饰的脂质组合物及其用途
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
EP4698150A1
(en)
|
2023-04-19 |
2026-02-25 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
AU2024349035A1
(en)
*
|
2023-09-27 |
2026-04-09 |
Hanmi Pharm. Co., Ltd. |
Non-natural 5'untranslated region and use thereof
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
US20260043035A1
(en)
|
2024-08-08 |
2026-02-12 |
Invaio Sciences, Inc. |
Nature-derived lipid particles for use in agriculture
|